Cauldron closes $13.25M Series A2, no sales team disclosed
## The Numbers Cauldron, an Orange NSW biotech, closed a $13.25 million Series A2 led by Main Sequence Ventures. Total funding now sits at roughly $26 million across seed ($10.5M in 2023) and Series A ($9.5M in 2024). The company develops continuous precision fermentation tech that cuts costs 30-50% versus traditional batch methods. Applications span food, agriculture, biofuels, cosmetics, and chemicals. ## What We Don't Know No public data on: - Sales team size or structure - Recent hires or hiring plans - CRO, VP Sales, or senior go-to-market roles - Compensation ranges for any roles - Revenue numbers or ARR For a company citing "faster-than-expected demand" and planning multi-facility expansion, the absence of sales org details is notable. Either they are not hiring yet, or the information is not public. ## The Context Cauldron runs a 25,000-litre facility in Orange, acquired via seed funding from CEO Michele Stansfield's prior firm Agritechnology (which included 35 years of R&D). Plans include a 500,000-litre facility and a network of plants across regional Australia. The company holds Australia's first 10,000-litre gene tech licence for scale testing. Fast Company named them among Asia-Pacific's most innovative companies this week. ## What This Means for Sales Pros Biotech startups at this stage typically build commercial teams post-Series A, especially when citing customer demand. If Cauldron starts hiring AEs or business development roles, expect: - Technical sales requirements (bioprocessing knowledge) - Long sales cycles (industrial contracts) - Enterprise deal sizes - Regional NSW or Sydney-based roles Worth tracking if you are looking at early-stage deep tech sales. Just do not expect comp transparency yet. **Series B equity note:** At $26M raised, Cauldron sits between Series A and B. Early-stage biotech comp typically skews toward equity over cash, with OTE structures less common than tech SaaS roles until commercial traction is proven.